Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426